Bukwang Pharmaceutical Co., Ltd. (003000.KS) Stock

003000.KS logo

Bukwang Pharmaceutical Co., Ltd.

003000.KSSouth Korea
Healthcare

Company profile

Bukwang Pharmaceutical reported revenue of 200.71 billion KRW for fiscal year 2025. In Q1 2026 (the quarter ended March 31, 2026) revenue was 47.78 billion KRW. South Korea was its largest region in fiscal year 2024, with 100% of revenue. In Q1 2026 it reported net income of 1.18 billion KRW, against a net loss of 69.12 million KRW a year earlier. Our analysis of its filings shows revenue growing from 125.93 billion KRW in fiscal year 2023 to 200.71 billion KRW in fiscal year 2025, 26.2% a year on average. Bukwang Pharmaceutical reports about 630 full-time employees.

What stands out

  • Revenue rose 25.4% in fiscal year 2025, from 160.09 billion KRW in fiscal year 2024, after a rise of 27.1% the year before.
  • It returned to a profit in fiscal year 2025, 12.56 billion KRW, after 4 years of net losses (2.64 billion KRW in fiscal year 2024).
  • Revenue turned down in Q1 2026: down 0.1% from a year before.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Bukwang Pharmaceutical Co., Ltd.

Bukwang Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products in South Korea and internationally. It offers its products in oral solid dosage forms, injections, oral solutions, external solutions, and ointments. The company also provides ethical drugs, including drugs for treating diabetic peripheral neuropathy, hypothyroidism, toxic liver disease, chronic hepatitis, liver cirrhosis, and iron-deficiency anemia; over-the-counter drugs, such as fever and pain relief medication, gastrointestinal medication, cold medication, laxatives for constipation, collagen supplements, multivitamin supplements, mouthwash, topical gels, oral health supplements, and omega-3 supplements; and personal products comprising toothpastes, toothbrushes, and other oral care products; nutraceuticals; health functional foods; and quasi drugs. In addition, it offers products for various threptic areas, including endocrinology, gastroenterology, cardiology, oncology, central nervous system, iron supplements, neuropsychiatry, respiratory/allergy, dermatology, urology, and other treatment areas. Further, the company's development pipeline comprises Lurasidone for the treatment of schizophrenia and bipolar depression; JM-010, for treating dyskinesia in parkinson's disease; SOL-804, which is used for the treatment of metastatic castration resistant prostate cancer; AhR Inhibitor for solid tumors; PKR Inhibitor for neurodegenerative disorders; and PD Program for parkinson's disease. Bukwang Pharmaceutical Co., Ltd. was founded in 1960 and is headquartered in Seoul, South Korea.

Largest shareholders

  • Oci Holdings Company Ltd.17.11%
  • Dong-Yeon Kim7.149 %7.15%
  • Chang-soo Jeong6.132 %6.13%
  • Sang-Hoon Kim0.5762 %0.58%
  • Bukwang Pharmaceutical Co., Ltd. ESOA0.23%

Share of the company, as of September 25, 2026

Leadership

  • Jae-Young Lee — Chief Executive Officer
  • Sung-Gu Lee — President & Director, 71
  • Won-Tae Park — Managing Director and Director, 73
  • Tae-Hyun Kim — Vice President, 73
  • Sang-Hoon Kim — Senior Managing Director, Head of Planning Adjustment Department and Representative Director, 57

How much revenue does Bukwang Pharmaceutical make?

Bukwang Pharmaceutical reported 200.71 billion KRW in revenue for fiscal year 2025, up 25.4% from 160.09 billion KRW in fiscal year 2024. In Q1 2026 revenue was 47.78 billion KRW.

Where does Bukwang Pharmaceutical make most of its revenue?

South Korea: 100% of revenue by region in fiscal year 2024, followed by Overseas (under 1%).

What companies are similar to Bukwang Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Daewoong Co., Ltd. (003090.KS), JW Pharmaceutical Corporation (001060.KS), Shinpoong Pharmaceutical Co.,Ltd (019170.KS), Ildong Pharmaceutical Co., Ltd. (249420.KS).

How has Bukwang Pharmaceutical's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 182.49 billion KRW; FY2022, 190.91 billion KRW; FY2023, 125.93 billion KRW; FY2024, 160.09 billion KRW; FY2025, 200.71 billion KRW.

Has Bukwang Pharmaceutical made a profit in recent years?

Net income by fiscal year: FY2021, a loss of 916.62 million KRW; FY2022, a loss of 2.47 billion KRW; FY2023, a loss of 31.33 billion KRW; FY2024, a loss of 2.64 billion KRW; FY2025, 12.56 billion KRW. It reported a net loss in 4 of these 5 years.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees630
HeadquartersSeoul, South Korea
ExchangeKSE
TimezoneAsia/Seoul (KST)

Contact & Links

Address
7, Sangdo-ro, Seoul, 06955
Phone
82 2 828 8114
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Bukwang Pharmaceutical Co., Ltd. (003000.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/003000.KS

LinkedInLinkedInXXYouTubeYouTube